Skip to main content
Log in

Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter

  • Letter to the Editors
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Alteplase has been shown to be effective in preventing central venous access clotting in patients on hemodialysis. Because of a high phosphorus content in its excipient, it can inadvertently contaminate blood samples, leading the physician in care of the patient to erroneously increase dialysis time or change diet in order to control the pseudo-hyperphosphatemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Dunea G, Domenico L, Gunnerson P, Winston-Willis F (1991) A survey of permanent double lumen catheters in hemodialysis patients. ASAIO Trans 37:M276–277

    PubMed  Google Scholar 

  2. Daeihagh P, Jordan P, Chen J, Rocco M (2000) Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 36:75–79

    PubMed  Google Scholar 

  3. Gittins M, Coulthard MG, Matthews JNS (2005) Alteplase v Heparin locks to maintain central line patency in hemodialysis lines. Arch Dis Child 90 [Suppl 11]:A30

  4. Schenk P, Rosenkranz AR, Wolfl G, Horl WH, Traindl O (2000) Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. Am J Kidney Dis 35:130–136

    PubMed  Google Scholar 

  5. McBryde KD, Wilcox J, Kher KK (2005) Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol 20:1182–1185

    Article  PubMed  Google Scholar 

  6. Rowe RC, Sheskey PJ, Weller PJ (2003) Handbook of pharmaceutical excipients, 4th edn. Pharmaceutical Press, London, pp 442–443

  7. Ball CL, Tobler K, Ross BC, Connors MR, Lyon ME (2004) Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter. Clin Chem Lab Med 42:107–108

    Article  PubMed  Google Scholar 

  8. Cohen AM, Magazanik A, van-der Lijn E, Shaked P, Levinsky H (1994) Pseudohyperphosphatemia incidence in an automatic analyzer. Eur J Clin Chem Clin Biochem 32:559–561

    PubMed  Google Scholar 

  9. Mandry JM, Posner MR, Tucci JR, Eil C (1991) Hyperphosphatemia in multiple myeloma due to a phosphate binding immunoglobulin. Cancer 68:1092–1094

    PubMed  Google Scholar 

  10. Lelhey DJ, Daugirdas JT, Ing TS, Reid RW (1985) Spurious hyperphosphatemia due to hyperlipidemia. Arch Int Med 145:743–744

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Francois Cachat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cachat, F., Bardy, D., Durussel, C. et al. Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter. Pediatr Nephrol 21, 301–302 (2006). https://doi.org/10.1007/s00467-005-2088-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-005-2088-1

Keywords

Navigation